Back To Search Results

Activated Charcoal

Editor: Alan Taylor Updated: 4/26/2023 1:55:29 PM


An oral suspension of activated charcoal (AC) should merit consideration in poisonings when there is an indication for gastrointestinal decontamination of an ingested toxin, and the clinician can administer activated charcoal within 1 hour of ingestion. Careful consideration of the contraindications (see below) should occur before activated charcoal treatment.[1][2][3] While activated charcoal has been shown to significantly reduce the absorption of many ingested toxins when given within the first-hour post-ingestion, no studies have shown patient-oriented outcome benefits such as mortality, morbidity, or length of hospital stay with the use of activated charcoal.[4]

Observational trial data in recent years suggests single-dose activated charcoal (SDAC) may be given and could significantly reduce drug absorption and bioavailability in the following circumstances:

  • In anticipation of serious toxicity
  • When the toxin ingestion occurs within 1 hour of administration, the decrease in absorption of the ingested toxin after 1-hour post-ingestion is unlikely to have clinical efficacy with the exceptions noted below.
  • Activated charcoal administration may be beneficial if administered up to 4 hours after large ingestions, ingestions of delayed-release drugs, and ingesting substances with anticholinergic or opioid properties that decrease intestinal motility.[5]
  • In alert and cooperative patients
  • When airway reflexes are intact, or there is airway protection by an endotracheal tube
  • Ingestions of toxins without specific antidotes
  • The ingested toxin is known to be adsorbed by charcoal (see below)  

Multiple-dose activated charcoal (MDAC) is often a consideration in cases of life-threatening ingestions of carbamazepine, dapsone, phenobarbital, quinine, and theophylline.[6]

Hatanaka K. et al. reported two cases of lamotrigine overdose. Multiple doses of activated charcoal were used for treatment. The investigators believe that the activated charcoal treatment shortened the elimination half-life of lamotrigine by decreasing enterohepatic recycling.[7]

Störmann S. et al. reported on a suicidal patient who ingested a large dose of chloroquine and diazepam.[8] The patient received treatment with activated charcoal, vasopressors, and diazepam. The patient survived.

Maes al. reported on a suicidal patient who ingested Digitalis purpurea (Foxglove) leaves. The patient initially received treatment with digitoxin-specific Fab fragments. Multi-dose activated charcoal was added to the treatment regimen to decrease absorption and enterohepatic recycling of the cardiac glycosides, e.g., digoxin from the Digitalis purpurea leaves in the patient’s GI tract.[9]

Ajjampur K. and Subramaniam A. reported on a suicidal patient who consumed a toxic dose of caffeine. The patient received treatment with a beta-blocker and activated charcoal which saved the patient’s life.[10]

An unlabeled use for activated charcoal is the treatment of inadvertent gluten ingestion by patients with celiac disease. However, there is a lack of clinical evidence to support this use.[11]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Activated charcoal adsorbs ingested toxins within the gastrointestinal tract preventing the systemic absorption of that toxin. Activated charcoal only adsorbs toxins that are in the dissolved liquid phase via direct contact. Orally administered activated charcoal does not get absorbed through the gastrointestinal lumen and acts within the gastrointestinal (GI) tract in its unchanged form. Ingested toxins come in contact with activated charcoal if the drug has not yet been absorbed from the gastrointestinal lumen or via recirculation of the toxin into the gut lumen by either enterohepatic recirculation, or entero-enteric recirculation through active secretion, or passive diffusion.

Activated charcoal adsorption of toxins is based on the equilibrium between the free toxin and the activated charcoal/toxin complex. Desorption of the toxin from activated charcoal may occur. However, in the presence of adequate doses of activated charcoal, the equilibrium is shifted towards the activated charcoal/toxin complex. This attempt to shift the equilibrium in favor of activated charcoal/toxin complexes is the rationale for dosing activated charcoal to activated charcoal: toxin ratio of 10 to 1 (see below).

Activated charcoal best adsorbs toxins in their nonionized forms. Polar, water-soluble molecules are less likely to be adsorbed. Due to the pharmacodynamics of activated charcoal, it best absorbs nonpolar, poorly water-soluble organic toxins.[12]

Most ingested toxins will have decreased systemic absorption in the presence of activated charcoal, including acetaminophen, aspirin, barbiturates, tricyclic antidepressants, theophylline, phenytoin, and a majority of inorganic and organic materials.[13][14][15][14] It is important to note that activated charcoal does not effectively adsorb alcohols, metals such as iron and lithium, electrolytes such as magnesium, potassium, or sodium, and acids or alkalis due to the polarity of these substances.


Clinicians should administer activated charcoal when they believe an ingested toxin is still in the gastrointestinal tract and when the benefits of preventing the absorption of the toxin are assumed to outweigh the risks posed by administering activated charcoal. The optimal dosing of activated charcoal is unknown. Activated charcoal administration can be oral or via nasogastric and orogastric tubes. When the dose of the ingested toxin is known, experts recommend activated charcoal at a 10 to 1 ratio of activated charcoal to the ingested toxin. This ratio may be impractical when the patient has ingested large doses of a toxin.[16] When the amount of toxin ingested is unknown, or it is impractical to achieve a 10 to 1 ratio in large dose toxic ingestions, SDAC should be administered at a dose of 1 g/kg of body weight or using a simplified age-based dosing scheme:

  • SDAC dosing adult: 50 to 100 g
  • SDAC dosing infants younger than one year: 10 to 25 g
  • SDAC children 2 to 12 years: 25 to 50 g
  • SDAC children older than 12 years: follow adult dosing

Multiple-dose activated charcoal (MDAC) refers to the administration of two or more sequential doses of activated charcoal for enhanced elimination of the ingested toxin. MDAC appears to prevent ongoing absorption of drug remaining within the GI tract and enhance elimination via enterohepatic or entero-enteric recirculation. While the quality of clinical data is not robust, researchers believe MDAC is beneficial for “potentially life-threatening” ingestions of carbamazepine, dapsone, phenobarbital, quinine, and theophylline.  

Dosing strategies of MDAC vary. The initial dosing is either a 10 to 1 ratio of activated charcoal to the toxin or 1 g/kg of bodyweight. Interval MDAC doses range from 0.25 to 0.5 g/kg of body weight every 1 to 6 hours in adults. Some cases have employed the continuous administration of activated charcoal through an NG tube. A simplified MDAC approach for adult patients would be:

  • A loading dose of 25 to 100 g
  • Repeat doses of 10 to 25 g of activated charcoal every 2 to 4 hours

Due to the variability in proper dosing strategies and indications for MDAC administration, it would be reasonable to consult a regional toxicologist or Poison Control Center before initiating MDAC therapy.

Formulations have been attempted to increase the palatability of activated charcoal, which is black and has a gritty texture. Ready-to-use aqueous suspensions of activated charcoal are available in 15 g, 25 g, and 50 g doses and formulations premixed with sorbitol. If activated charcoal is not premixed, a slurry can be made with activated charcoal in a 1 to 8 ratio of activated charcoal to a suitable liquid such as water, cola, or flavored syrups. Offering activated charcoal in an opaque cup with a lid and straw is an easy way to increase the palatability of activated charcoal.

Adverse Effects

Pulmonary aspiration and a resulting aspiration pneumonitis are the most concerning risks of administration of activated charcoal. Aspiration from emesis and misplaced nasogastric tubes for activated charcoal administration can lead to severe respiratory compromise and even death. Therefore, an adequate airway assessment must occur before activated charcoal administration. In patients with a depressed level of consciousness, providers must consider the risk-to-benefit ratio of intubation for airway protection and the therapeutic benefits of activated charcoal. Emesis occurs more often with rapid administration of activated charcoal, and the risk of emesis increases when the activated charcoal has sorbitol added. Patients should be monitored for mental status changes and continued airway protection if emesis occurs. 

While emesis is a common adverse effect, more significant gastrointestinal complications such as bowel obstructions have been reported after the administration of activated charcoal. Patients with pre-existing motility disorders, those receiving opioids or antimuscarinic drugs, and those treated with MDAC might be at greater risk. However, the likelihood of a more significant gastrointestinal complication following SDAC therapy is low.[4]


A position statement from the American Academy of Clinical Toxicology (AACT) in 2005 lists the following as contraindications and relative contraindications for activated charcoal use:

  • Patients with an unprotected airway (in other words, a depressed level of consciousness) without endotracheal intubation
  • If activated charcoal use is likely to increase the risk and severity of aspiration of a toxin (hydrocarbons with high aspiration potentials)
  • When the threat of GI perforation or hemorrhage is high secondary to medical conditions or recent surgery
  • When endoscopy is likely to be attempted as activated charcoal may obscure endoscopic visualization
  • In the presence of an intestinal obstruction
  • When activated charcoal is known to not meaningfully adsorb the ingested toxin such as metals, acids, alkalis, electrolytes, or alcohols

MDAC is relatively contraindicated if decreased peristalsis is likely to occur from the substance ingested (opioids or anticholinergics). If these patients receive MDAC, they should be monitored closely for the development of obstruction or potential aspiration.


As activated charcoal remains inert within the GI tract, no therapeutic index for systemic absorption exists.


No significant toxicity from activated charcoal exists as it is not systemically absorbed; however, adverse effects from the administration, as listed above, such as emesis, aspiration, and bowel obstruction, can occur.

Enhancing Healthcare Team Outcomes

Activated charcoal is widely used in emergency departments to treat many types of toxic ingestions. Its use significantly prevents the absorption of many toxic drugs and other poisons if given early post-ingestion. However, patient-oriented outcome data for the benefit of activated charcoal is limited, and its administration is not without risk. Healthcare professionals in the emergency department, including nurses, pharmacists, and physicians, need to know when and how to use activated charcoal for the best results. While activated charcoal is widely sold in health food stores to treat various conditions, it is important to educate the patient about the harm of the unregulated use of this substance.[4][17]

A clinician contemplating the use of activated charcoal should consider consulting with a clinical pharmacist, toxicologist, or Poison Control if there are any doubts regarding the appropriateness of its use. These resources can also assist with appropriate dosing and administration. Nurses will administer the activated charcoal and should help monitor the patient for adverse events as well as assess the effectiveness of the intervention. Communication between team members is essential, as is documenting any interventions and patient responses to treatment. Functioning as a collaborative interprofessional team will optimize patient outcomes when using activated charcoal for toxic substance ingestions. [Level 5]



Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. The Cochrane database of systematic reviews. 2018 Feb 23:2(2):CD003328. doi: 10.1002/14651858.CD003328.pub3. Epub 2018 Feb 23     [PubMed PMID: 29473717]

Level 1 (high-level) evidence


Park S, Lee HJ, Shin J, You KM, Lee SJ, Jung E. Clinical Effects of Activated Charcoal Unavailability on Treatment Outcomes for Oral Drug Poisoned Patients. Emergency medicine international. 2018:2018():4642127. doi: 10.1155/2018/4642127. Epub 2018 Oct 3     [PubMed PMID: 30402289]


Thomsen M, Vitetta L. Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis. Integrative cancer therapies. 2018 Dec:17(4):1027-1047. doi: 10.1177/1534735418794885. Epub 2018 Aug 23     [PubMed PMID: 30136590]


Juurlink DN. Activated charcoal for acute overdose: a reappraisal. British journal of clinical pharmacology. 2016 Mar:81(3):482-7. doi: 10.1111/bcp.12793. Epub 2015 Nov 9     [PubMed PMID: 26409027]


Hoegberg LCG, Shepherd G, Wood DM, Johnson J, Hoffman RS, Caravati EM, Chan WL, Smith SW, Olson KR, Gosselin S. Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose. Clinical toxicology (Philadelphia, Pa.). 2021 Dec:59(12):1196-1227. doi: 10.1080/15563650.2021.1961144. Epub 2021 Aug 23     [PubMed PMID: 34424785]

Level 1 (high-level) evidence


Takia L, Kc S, Randhawa M, Angurana SK, Nallasamy K, Bansal A, Jayashree M. Clinical Features, Intensive Care Needs, and Outcome of Carbamazepine Poisoning in Children. Indian journal of pediatrics. 2022 Oct:89(10):1022-1024. doi: 10.1007/s12098-022-04155-7. Epub 2022 Mar 12     [PubMed PMID: 35277811]


Hatanaka K, Kamijo Y, Kitamoto T, Hanazawa T, Yoshizawa T, Ochiai H, Haga Y. Effectiveness of multiple-dose activated charcoal in lamotrigine poisoning: a case series. Clinical toxicology (Philadelphia, Pa.). 2022 Mar:60(3):379-381. doi: 10.1080/15563650.2021.1953518. Epub 2021 Aug 18     [PubMed PMID: 34405740]

Level 2 (mid-level) evidence


Störmann S, Hoppe J, Steinert D, Angstwurm MW. A Case of Self-salvation in a Determined Chloroquine Suicide Attempt. Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures). 2022 Jan:8(1):61-65. doi: 10.2478/jccm-2021-0036. Epub 2021 Nov 13     [PubMed PMID: 35274057]

Level 3 (low-level) evidence


Maes KR, Depuydt P, Vermassen J, De Paepe P, Buylaert W, Lyphout C. Foxglove poisoning: diagnostic and therapeutic differences with medicinal digitalis glycosides overdose. Acta clinica Belgica. 2022 Feb:77(1):101-107. doi: 10.1080/17843286.2020.1773652. Epub 2020 Jun 4     [PubMed PMID: 32496148]


Ajjampur K, Subramaniam A. The importance of early use of beta blockers and gastric decontamination in caffeine overdose: A case report. Australian critical care : official journal of the Confederation of Australian Critical Care Nurses. 2021 Jul:34(4):395-400. doi: 10.1016/j.aucc.2020.09.007. Epub 2020 Oct 31     [PubMed PMID: 33131980]

Level 3 (low-level) evidence


Espinoza B, Zingale D, Rubal-Peace G. Prevalence of medically unsupervised activated charcoal use a cause for concern in celiac disease? Journal of the American Pharmacists Association : JAPhA. 2022 Mar-Apr:62(2):546-550. doi: 10.1016/j.japh.2021.10.026. Epub 2021 Oct 25     [PubMed PMID: 34764035]


Chacko B, Peter JV. Antidotes in Poisoning. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine. 2019 Dec:23(Suppl 4):S241-S249. doi: 10.5005/jp-journals-10071-23310. Epub     [PubMed PMID: 32020997]


Chiew AL, Buckley NA. Acetaminophen Poisoning. Critical care clinics. 2021 Jul:37(3):543-561. doi: 10.1016/j.ccc.2021.03.005. Epub     [PubMed PMID: 34053705]


Chomchai S, Mekavuthikul P, Phuditshinnapatra J, Chomchai C. Sensitivity of dose-estimations for acute acetaminophen overdose in predicting hepatotoxicity risk using the Rumack-Matthew Nomogram. Pharmacology research & perspectives. 2022 Feb:10(1):e00920. doi: 10.1002/prp2.920. Epub     [PubMed PMID: 35106928]

Level 3 (low-level) evidence


Isoardi KZ, Henry C, Harris K, Isbister GK. Activated Charcoal and Bicarbonate for Aspirin Toxicity: a Retrospective Series. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2022 Jan:18(1):30-37. doi: 10.1007/s13181-021-00865-0. Epub 2021 Nov 29     [PubMed PMID: 34845647]

Level 2 (mid-level) evidence


Delaney TM, Helvey JT, Shiffermiller JF. A Case of Salicylate Toxicity Presenting with Acute Focal Neurologic Deficit in a 61-Year-Old Woman with a History of Stroke. The American journal of case reports. 2020 Feb 15:21():e920016. doi: 10.12659/AJCR.920016. Epub 2020 Feb 15     [PubMed PMID: 32060256]

Level 3 (low-level) evidence


Ferranti S, Grande E, Gaggiano C, Grosso S. Antiepileptic drugs: Role in paediatric poisoning. Journal of paediatrics and child health. 2018 May:54(5):475-479. doi: 10.1111/jpc.13833. Epub 2018 Jan 2     [PubMed PMID: 29292550]